Drugs / Bergamot
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03090750 | Jul 2015 → Dec 2016 | anxiety | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03676309 Comparator | Sep 2017 → Mar 2018 | type 2 diabetes mellitus, vascular disorder | Villa dei Gerani | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bergamot | “nutraceutical 920 mg (Bergamot 450 mg, Gymnema (400 mg, Phaseolamine 30 mg, Olea Europaea 10 mg) twice day , 12 weeks” NCT03676309 ↗ |
| Known as | Bergamot Oil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03090750 ↗ |
| Route | Other | “Bergamot essential oil applied to cotton ball (3 drops) and placed in a medicine cup on bedside table” NCT03090750 ↗ |